Science
Ahmed Alanazi: Phase III KRASCENDO 1 Reports Superior Efficacy of Divarasib in KRAS G12C–Mutated NSCLC
Ahmed Alanazi/LinkedIn

Ahmed Alanazi: Phase III KRASCENDO 1 Reports Superior Efficacy of Divarasib in KRAS G12C–Mutated NSCLC

Ahmed Alanazi, Head of Hematology,Oncology Clinical Pharmacy Section at King Fahad Medical City – KFMCK, shared a post on X:

“Krascendo 1 (Phase 3)

  • First head-to-head KRAS G12C inhibitor trial
  • First KRAS G12C inhibitor to improve OS in NSCLC

Divarasib vs sotorasib/adagrasib, pretreated KRAS G12C NSCLC (N=338)

  • mOS 17.7 vs 12.0 mo (HR 0.56)
  • mPFS 9.8 vs 5.7 mo (HR 0.58)
  • ORR 58% vs 32%”

Ahmed Alanazi: Phase III KRASCENDO 1 Reports Superior Efficacy of Divarasib in KRAS G12C–Mutated NSCLC

You may also be interested in:

Krascendo 1 Phase III: Divarasib Significantly Improves Overall Survival and Progression-Free Survival Versus Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC

Ahmed Alanazi: Phase III KRASCENDO 1 Reports Superior Efficacy of Divarasib in KRAS G12C–Mutated NSCLC

Ahmed Alanazi cancer cancer care cancer treatment Divarasib ESMO esmo 2026 KRAS G12C inhibitor KRASCENDO-1 NSCLC OncoDaily Oncology sotorasib/adagrasib